Relative Bioavailability Clinical Trial
Official title:
To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers in Chinese Adult Male Healthy Volunteers
This is a single-center, randomized, open, single-dose, three-cycle cross-design study, which will be only enrolled Chinese male healthy volunteers.
27-30 Chinese male healthy volunteers will be enrolled to assess the pharmacokinetic profile and relative bioavailability of 300 mg (50 mg x 6) Sulfatinib capsules of single dose orally in two different manufacturers after breakfast. All subjects are required to collect PK blood samples before and after administration at the following time points: within 1 hour before administration, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48, 72, 96 hours after administration (16 times point), each collection of venous blood is 2mL. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02052349 -
Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01911741 -
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT03154840 -
Relative Bioavailability Among Different Eutropin Formulations
|
Phase 1 | |
Completed |
NCT04814472 -
Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations
|
Phase 1 | |
Completed |
NCT03934333 -
A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)
|
Phase 1 | |
Not yet recruiting |
NCT06025344 -
A Relative Bioavailability Study With a Novel PanCytoVirâ„¢ Oral Suspension (100 mg/ml)
|
Phase 1 | |
Not yet recruiting |
NCT06025318 -
An Evaluation of the Effect of Food on the PK of a Novel PanCytoVirâ„¢ Suspension (100mg/ml), in Healthy, Adult Volunteers
|
Phase 1 | |
Completed |
NCT04686669 -
A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations
|
Phase 1 | |
Completed |
NCT05296382 -
Bioavailability of Tebipenem (SPR994) Crushed Tablet
|
Phase 1 |